1
00:00:00,000 --> 00:00:03,500
Mazdutide activates GLP-1 and glucagon receptors.

2
00:00:03,500 --> 00:00:10,583
Its GLORY-1 study offers a useful example of why the trial population belongs alongside the result.

3
00:00:10,583 --> 00:00:17,250
The 2025 randomized, placebo-controlled phase three trial enrolled 610 adults in China with obesity or

4
00:00:17,250 --> 00:00:21,500
overweight. Primary weight endpoints were assessed at week 32.

5
00:00:21,500 --> 00:00:27,375
Mazdutide groups lost more weight than placebo, with additional follow-up through week 48.

6
00:00:27,375 --> 00:00:32,833
The most frequently reported adverse events were gastrointestinal, generally mild or moderate.

7
00:00:32,833 --> 00:00:37,083
Findings should retain their population, duration, and study conditions.

8
00:00:37,083 --> 00:00:42,958
Comparing headline percentages from unrelated trials cannot establish a winner, and regulatory decisions

9
00:00:42,958 --> 00:00:46,458
must be checked separately for each jurisdiction.